Little Green Pharma Completes Transformational Cannatrek Merger
Little Green Pharma Ltd (ASX: LGP) has successfully completed its merger with Cannatrek Ltd, creating one of Australia’s largest and most diversified medicinal cannabis groups. Under the scheme of arrangement, LGP acquired 100% of Cannatrek’s issued share capital, with former Cannatrek shareholders holding approximately 60.5% of the merged entity’s fully diluted capital and existing LGP shareholders holding about 39.5%. The transaction combines complementary strengths across cultivation, manufacturing, distribution, clinics, digital health platforms, brands and export operations spanning Australia and Europe.
The merged group is expected to benefit from greater scale, stronger operational capabilities, wider distribution networks and enhanced financial resources, supporting future expansion opportunities in Europe and other regulated medicinal cannabis markets. Leadership changes include Brent Dennison becoming Independent Non-Executive Chair, while Paul Long continues as Group CEO. The company believes the combined business is well positioned to capitalize on industry consolidation trends and pursue long-term international growth initiatives.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au
x
Daily Dose of Buy, Sell & Hold recommendations before the market opens.
Start Your 7 Days Free Trial Now!
We use cookies to help us improve, promote, and protect our services.
By continuing to use this site, we assume you consent to this.
Read our
Privacy Policy
and
Terms & Conditions
Little Green Pharma Completes Transformational Cannatrek Merger
Little Green Pharma Ltd (ASX: LGP) has successfully completed its merger with Cannatrek Ltd, creating one of Australia’s largest and most diversified medicinal cannabis groups. Under the scheme of arrangement, LGP acquired 100% of Cannatrek’s issued share capital, with former Cannatrek shareholders holding approximately 60.5% of the merged entity’s fully diluted capital and existing LGP shareholders holding about 39.5%. The transaction combines complementary strengths across cultivation, manufacturing, distribution, clinics, digital health platforms, brands and export operations spanning Australia and Europe.
The merged group is expected to benefit from greater scale, stronger operational capabilities, wider distribution networks and enhanced financial resources, supporting future expansion opportunities in Europe and other regulated medicinal cannabis markets. Leadership changes include Brent Dennison becoming Independent Non-Executive Chair, while Paul Long continues as Group CEO. The company believes the combined business is well positioned to capitalize on industry consolidation trends and pursue long-term international growth initiatives.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au